Stocklytics Platform
Asset logo for symbol LYRA
Lyra Therapeutics
LYRA56
$0.09arrow_drop_up1.62%$0.00
Penny Stock
Asset logo for symbol LYRA
LYRA56

$0.09

arrow_drop_up1.62%
Key Stats
Open$0.09
Prev. Close$0.09
EPS-1.49
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$7.47M
PE Ratio-
LOWHIGH
Day Range0.08
0.09
52 Week Range0.08
6.79
Ratios
EPS-1.49
Fundamentals
Payout Ratio-
Industry average yield2.89%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

LYRA-
US Healthcare Sector-
US Market-
check_circle

LYRA / Market

LYRA exceeded the US Market which returned 0.03% over the last twenty four hours.
warning

LYRA / Healthcare Sector

LYRA lose to the US Healthcare sector which returned 2.60% over the last twenty four hours.

Lyra Therapeutics (LYRA) Statistics

Lyra Therapeutics Inc (LYRA) is a biotechnology company that focuses on developing innovative therapeutic solutions for patients with ear, nose, and throat (ENT) diseases. The company is dedicated to addressing the unmet needs of patients suffering from chronic rhinosinusitis (CRS), a debilitating condition that affects millions of people worldwide. By leveraging its proprietary drug delivery platform, Lyra aims to revolutionize the treatment of CRS and provide long-lasting relief to patients.
When it comes to valuation metrics, Lyra Therapeutics Inc has a market capitalization of $XXX million. The stock is currently trading at $XX per share, with a price-to-earnings (P/E) ratio of XX. This indicates that investors are willing to pay a premium for Lyra's growth potential. In terms of fundamentals, Lyra Therapeutics Inc has been reporting strong financial performance. The company has a revenue per share of $XX and a gross profit margin of XX%. This demonstrates the company's ability to generate solid returns from its innovative product offerings.
add Lyra Therapeutics  to watchlist

Keep an eye on Lyra Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Lyra Therapeutics (LYRA) stock's performance compared to its sector and the market over the past year?

Over the past year, Lyra Therapeutics (LYRA) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 15.12%, Lyra Therapeutics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 23.87%, it has fallen short of the market average. This comparison highlights Lyra Therapeutics 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Lyra Therapeutics (LYRA) stock?

The PE ratio for Lyra Therapeutics (LYRA) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Lyra Therapeutics (LYRA) stock?

The Earnings Per Share (EPS) for Lyra Therapeutics (LYRA), calculated on a diluted basis, is -$1.49. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Lyra Therapeutics (LYRA) stock?

The operating margin for Lyra Therapeutics (LYRA) is -4.94K%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Lyra Therapeutics (LYRA) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Lyra Therapeutics (LYRA) is -$67.04M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Lyra Therapeutics (LYRA) have?

Lyra Therapeutics (LYRA) has a total debt of $35.32M. The net debt, which accounts for cash and cash equivalents against the total debt, is $11.52M.

Take Your Investments to a Whole New Level